(NASDAQ: MRVI) Maravai Lifesciences Holdings's forecast annual revenue growth rate of 5.59% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.47%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.58%.
Maravai Lifesciences Holdings's revenue in 2026 is $208,775,000.On average, 11 Wall Street analysts forecast MRVI's revenue for 2026 to be $56,050,551,956, with the lowest MRVI revenue forecast at $53,568,072,101, and the highest MRVI revenue forecast at $58,104,570,330. On average, 11 Wall Street analysts forecast MRVI's revenue for 2027 to be $59,717,143,541, with the lowest MRVI revenue forecast at $55,551,978,596, and the highest MRVI revenue forecast at $63,147,432,128.
In 2028, MRVI is forecast to generate $63,944,630,156 in revenue, with the lowest revenue forecast at $59,496,420,960 and the highest revenue forecast at $69,109,538,558.